The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
there's a biomarker called c2n I don't know if you guys are familiar with it it's a biomarker that we use clinically uh in in humans of course to look for um ameloid in the serum but it's very highly correlated with ameloid in the CNS and it's very highly Cor correlated with amalloy pet scans
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
so this c2n assay which was approved a couple of years ago has become a really important part of how we manage risk in our high-risk patients